Modicus Prime Raises Additional $4.5M in Funding

The company plans to use the funds to support its international pharmaceutical customers better, expand customer service, and continue improving its platform to handle customer deployments and growing AI compliance requirements.

Modicus Prime is helping lead the pharmaceutical industry’s adoption of AI through industry guidelines, webinars, keynote talks, and regulatory education. Taylor Chartier, the company’s CEO, co-authored the ISPE GAMP AI Guide and the BioPhorum AI Implementation publication in 2025, and also led ISPE’s first webinar series focused on using AI and machine learning in GxP environments, while continuing to support workforce education initiatives with organizations including Pathway for Patient Health.

Taylor Chartier, a former engineer and data scientist at Shire and Bayer, said that while pharmaceutical companies are investing heavily in AI, many still lack the compliance systems needed to deploy AI and measure its value safely, a challenge also faced by healthcare payers and providers, which Modicus Prime aims to solve with its Trustworthy AI Compliance Software for regulated industries.

Modicus Prime’s Trustworthy AI Compliance Software helps pharmaceutical companies manage AI applications in regulated environments and keep them audit-ready across different teams, systems, and global locations. The platform connects with existing technology and quality management systems, creating a single source for AI compliance with regulators such as the FDA and EMA.

The software also helps data science, IT, quality, and compliance teams work together more efficiently while reducing compliance risks and protecting AI investments. Supporting safe and scalable AI adoption can help pharmaceutical companies avoid costly quality control issues and stay focused on delivering medicines to patients.

Read More:Astranis Raises $455M in Funding Led by Snowpoint Ventures

Oncology Ventures' Ben Freeberg states, "The next wave of cancer breakthroughs is coming, and every manufacturer has to survive a regulatory audit to ensure those drugs get to patients who need them. Modicus Prime is the compliance layer that makes this happen."

FCV founding partner Senator Bill Frist, MD, states, "At the end of the day, every advancement in this industry must serve the patient. By simplifying and strengthening AI compliance, Modicus Prime enables pharmaceutical leaders to stay focused on accelerating innovation and delivering life-saving therapies to those who need them most."

About Modicus Prime

Founded in 2020, Modicus Prime provides an AI compliance platform that helps regulated organizations safely deploy, and scale AI by connecting data science IT and quality teams. The platform creates a single source of truth for regulators, ensuring AI systems remain compliant throughout their full lifecycle, and integrates with existing technology, and quality systems to support biologics, cell, and gene therapies, and vaccine manufacturing across global regulatory environments, while partnering with major pharmaceutical companies, and operating as a resident at Johnson & Johnson Innovation JLABS in South San Francisco.

Read More:SageOx Raises $15M in Seed Funding Led by Canaan Partners